Form 4 for RAPP Rapport Therapeutics, Inc.
Accepted 2026-01-05 00:00:00 ET · period of report 2025-12-31 · accession 0001193125-26-002470 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-05 | 2025-12-31 | RAPP | Bredt David | CSO | S - Sale | $30.05 | -6,567 | 404.1K | -2% | -$197.3K | |
| 2026-01-05 | 2025-12-31 | RAPP | Bredt David | CSO | A - Grant | — | -18.0K | 410.6K | -4% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-31 | S | D | 6,567 | $30.05 | 404,075 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.04 to $30.05. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| 2 | Common | Common Stock | 2025-12-31 | A | D | 18,000 | — | 410,642 | D | — | — | (F1) On December 4, 2024, the Reporting Person was granted performance-based restricted stock units ("PSUs") subject to the satisfaction of specified performance criteria as of December 31, 2025. The issuers Compensation Committee confirmed that the performance criteria had been met, resulting in the vesting of such PSUs effective December 31, 2025. |